Agouron deal

The companies will develop compounds intended to inactivate protease enzymes known to be required for replication of hepatitis C, viruses in the herpes family, and the rhinoviruses responsible for upper respiratory infections.

Japan Tobacco will pay AGPH a $7 million up-front fee, and has committed additional payments related to the anti-viral programs of not less than $8 million over two years, and of more than $21 million over four years if two preclinical research milestones are achieved. ...